نتائج البحث - Natarajan Muthusamy

تنقيح النتائج
  1. 1
    Tetraspanins as therapeutic targets in hematological malignancy: a concise review

    Tetraspanins as therapeutic targets in hematological malignancy: a concise review حسب Kyle A. Beckwith, John C. Byrd, Natarajan Muthusamy

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

    The clinical application of monoclonal antibodies in chronic lymphocytic leukemia حسب Samantha Jaglowski, Lapo Alinari, Rosa Lapalombella, Natarajan Muthusamy, John C. Byrd

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    The Ets-1 Transcription Factor Is Required for the Development of Natural Killer Cells in Mice

    The Ets-1 Transcription Factor Is Required for the Development of Natural Killer Cells in Mice حسب Kevin Barton, Natarajan Muthusamy, Christopher Fischer, Chao-Nan Ting, Theresa L. Walunas, Lewis L. Lanier, Jeffrey M. Leiden

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Human T-Cell Lymphotropic Virus Type 1 p12<sup>I</sup>Expression Increases Cytoplasmic Calcium To Enhance the Activation of Nuclear Factor of Activated T Cells

    Human T-Cell Lymphotropic Virus Type 1 p12<sup>I</sup>Expression Increases Cytoplasmic Calcium To Enhance the Activation of Nuclear Factor of Activated T Cells حسب Wei Ding, Björn Albrecht, Robert E. Kelley, Natarajan Muthusamy, Seung-Jae Kim, Ruth A. Altschuld, Michael D. Lairmore

    منشور في 2002
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders

    A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders حسب John M. Timmerman, John C. Byrd, David Andorsky, Reiko Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

    Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas حسب Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien‐Hsing Chang

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

    Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties حسب Sarwish Rafiq, Jonathan P. Butchar, Carolyn Cheney, Xiaokui Mo, Rossana Trotta, Michael A. Caligiuri, David Jarjoura, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

    Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia حسب Amy J. Johnson, David Lucas, Natarajan Muthusamy, Lisa L. Smith, Ryan B. Edwards, Michael De Lay, Carlo M. Croce, Michael R. Grever, John C. Byrd

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

    Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia حسب Emily M. McWilliams, Jennifer M. Mele, Carolyn Cheney, Elizabeth A. Timmerman, Faraz Fiazuddin, Ethan Strattan, Xiaokui Mo, John C. Byrd, Natarajan Muthusamy, Farrukh T. Awan

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

    FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma حسب Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching‐Shih Chen, James T. Dalton, Natarajan Muthusamy, John C. Byrd

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis

    Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis حسب Wei Guo, Ruchika Srinivasan, Carmen Z. Cantemir-Stone, Sudarshana M. Sharma, Ramasamy Santhanam, Michael Weinstein, Natarajan Muthusamy, Albert K. Man, Robert G. Oshima, Gustavo Leone, Michael C. Ostrowski

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity

    Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity حسب Sara S. Alhakeem, Mary K. McKenna, Karine Z. Oben, Sunil K. Noothi, Jacqueline R. Rivas, Gerhard C. Hildebrandt, Roger A. Fleischman, Vivek M. Rangnekar, Natarajan Muthusamy, Subbarao Bondada

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

    PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression حسب Shuai Dong, Bonnie K. Harrington, Eileen Hu, J.T. Greene, Amy M. Lehman, Minh Tran, Ronni Wasmuth, Meixiao Long, Natarajan Muthusamy, Jennifer R. Brown, Amy J. Johnson, John C. Byrd

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

    The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia حسب Sarah E.M. Herman, Rosa Lapalombella, Amber Gordon, Asha Ramanunni, Kristie A. Blum, Jeffrey A. Jones, Xiaoli Zhang, Brian J. Lannutti, Kamal D. Puri, Natarajan Muthusamy, John C. Byrd, Amy J. Johnson

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

    Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity حسب Holbrook E. Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E.M. Herman, Jonathan P. Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Amy J. Johnson, John C. Byrd

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

    Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing حسب Jason A. Dubovsky, Danielle L. Chappell, Bonnie K. Harrington, Kitty Agrawal, Leslie A. Andritsos, Joseph M. Flynn, Jeffrey A. Jones, Michael E. Paulaitis, Brad Bolon, Amy J. Johnson, John C. Byrd, Natarajan Muthusamy

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    <i>Retracted:</i> Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

    <i>Retracted:</i> Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma حسب Hany A. Omar, Chih-Chien Chou, Lisa D. Berman-Booty, Yihui Ma, Jui‐Hsiang Hung, Dasheng Wang, Takayuki Kogure, Tushar Patel, Luigi Terracciano, Natarajan Muthusamy, John C. Byrd, Samuel K. Kulp, Ching‐Shih Chen

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia

    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia حسب Jacqueline R. Rivas, Y Liu, Sara S. Alhakeem, Joseph M. Eckenrode, Francesc Martí, James P. Collard, Yanbin Zhang, Khaled A. Shaaban, Natarajan Muthusamy, Gerhard Hildebrandt, Roger A. Fleischman, L Chen, Jon S. Thorson, Markos Leggas, Subbarao Bondada

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

    Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical حسب Zhao Xiaobin, Rosa Lapalombella, Trupti Joshi, Carolyn Cheney, Aruna Gowda, Martha Hayden-Ledbetter, Peter Baum, Thomas S. Lin, David Jarjoura, Amy Lehman, Donna Kussewitt, Robert J. Lee, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

    IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leu... حسب Aruna Gowda, Julie M. Roda, Syed-Rehan A. Hussain, Asha Ramanunni, Trupti Joshi, S. Schmidt, Xiaoli Zhang, Amy Lehman, David Jarjoura, William E. Carson, Wayne Kindsvogel, Carolyn Cheney, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: